Hill-Rom Holdings Inc (NYSE:HRC) has received an average recommendation of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $88.20.

A number of research analysts have weighed in on HRC shares. Zacks Investment Research upgraded shares of Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a research note on Monday, April 3rd. Barclays PLC boosted their target price on shares of Hill-Rom Holdings from $70.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, April 19th. Stifel Nicolaus boosted their target price on shares of Hill-Rom Holdings from $70.00 to $84.00 and gave the company a “buy” rating in a research note on Monday, May 1st. Finally, ValuEngine upgraded shares of Hill-Rom Holdings from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd.

Hill-Rom Holdings (NYSE:HRC) opened at 84.10 on Tuesday. The firm has a 50-day moving average of $80.64 and a 200 day moving average of $71.29. Hill-Rom Holdings has a 12-month low of $50.50 and a 12-month high of $84.65. The company has a market capitalization of $5.53 billion, a PE ratio of 36.33 and a beta of 1.23.

Hill-Rom Holdings (NYSE:HRC) last released its earnings results on Friday, April 28th. The medical technology company reported $0.88 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.09. The firm had revenue of $678.90 million for the quarter, compared to analysts’ expectations of $654.27 million. Hill-Rom Holdings had a net margin of 5.80% and a return on equity of 19.77%. The company’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.71 earnings per share. Analysts forecast that Hill-Rom Holdings will post $3.86 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 15th will be given a $0.18 dividend. This represents a $0.72 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Thursday, September 14th. Hill-Rom Holdings’s dividend payout ratio (DPR) is currently 31.03%.

In other news, SVP Paul Sherwood Johnson sold 2,078 shares of the business’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $72.30, for a total value of $150,239.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Andreas G. Frank sold 10,660 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $78.62, for a total transaction of $838,089.20. Following the completion of the sale, the senior vice president now directly owns 28,988 shares in the company, valued at approximately $2,279,036.56. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

Several hedge funds have recently bought and sold shares of HRC. GSA Capital Partners LLP acquired a new stake in Hill-Rom Holdings during the fourth quarter valued at about $235,000. Guggenheim Capital LLC raised its stake in Hill-Rom Holdings by 25.8% in the fourth quarter. Guggenheim Capital LLC now owns 52,379 shares of the medical technology company’s stock valued at $2,940,000 after buying an additional 10,738 shares during the period. Norges Bank acquired a new stake in Hill-Rom Holdings during the fourth quarter valued at about $36,707,000. Highbridge Capital Management LLC raised its stake in Hill-Rom Holdings by 92.9% in the fourth quarter. Highbridge Capital Management LLC now owns 422,467 shares of the medical technology company’s stock valued at $23,716,000 after buying an additional 203,502 shares during the period. Finally, Foundry Partners LLC raised its stake in Hill-Rom Holdings by 3.3% in the first quarter. Foundry Partners LLC now owns 188,507 shares of the medical technology company’s stock valued at $13,309,000 after buying an additional 6,039 shares during the period. 83.81% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/25/hill-rom-holdings-inc-hrc-given-consensus-recommendation-of-buy-by-brokerages.html.

About Hill-Rom Holdings

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom Holdings (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.